<DOC>
	<DOCNO>NCT00491608</DOCNO>
	<brief_summary>The purpose study evaluate safety immune system response recombinant thrombin use control bleed spinal vascular surgery .</brief_summary>
	<brief_title>Immunogenicity Safety Study Topical Recombinant Thrombin Surgical Hemostasis</brief_title>
	<detailed_description>This Phase 3b , open-label , single-group , multisite safety immunogenicity study recombinant thrombin ( rThrombin ) participant least 18 year age undergoing spinal vascular surgery . Eligible participant receive topical rThrombin surgery complete 1-month follow-up visit .</detailed_description>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Currently undergo cervical , thoracic , lumbar discectomy ; corpectomy , laminectomy , lateral interbody fusion , include anterior posterior approach ( include minimally invasive procedure ; arterial reconstruction ; peripheral artery bypass ( PAB ) grafting ; arteriovenous ( AV ) vascular access procedure History surgery high likelihood exposure bovine thrombin within past 3 year . Prior surgery must 1 follow open procedure : open procedure involve spine cranium , PAB grafting , AV vascular access procedure , autologous skin grafting , surgical procedure accompany documented treatment bovine thrombin Age 18 year young time inform consent If female childbearing potential : Negative pregnancy test result within 14 day prior treatment Use medically accept form contraception time inform consent completion followup study visit , sexually active male sexually active female childbearing potential Signed IRB/independent ethic committeeapproved informed consent document Currently undergo procedure require cardiopulmonary bypass involve aortic arch Known hypersensitivity rThrombin component Presence medical , social , psychosocial factor , opinion investigator , could impact safety compliance study procedure Breastfeeding Receipt treatment experimental agent within 30 day study enrollment treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Phase 3b</keyword>
	<keyword>rThrombin</keyword>
	<keyword>spine surgery</keyword>
	<keyword>vascular surgery</keyword>
	<keyword>hemostasis</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
</DOC>